BCAL DIAGNOSTICS LIMITED (ASX: BDX)
Health care · News and insights
BDX: $0.060 +0.00% · MC: $22M
Latest BDX announcements
Announcement Insights
BCAL Diagnostics Advances Test Research as Genetic Signatures Merger Dispute Emerges
BCAL Diagnostics has moved its breast-testing programme from validation toward commercial rollout while expanding research: BREASTESTplus 2 completed clinical validation in October, with launch targeted for November subject to accreditation and operational readiness, and Avantect Multicancer became available at selected locations. On 17 November, new ethics approval expanded breast cancer research to multiomic assay development, alongside publication of a lipidomics framework. Separately, BCAL asked the Takeovers Panel to intervene in Genetic Signatures’ proposed Microba merger, citing concerns over competing offers and shareholder information; the Panel had not decided whether to open proceedings.
Updated 17 Nov 2026, 08:57 AM Sydney time
Sources
BCAL Expands Breast Cancer Biomarker ProgramTOV: GSS - Panel Receives ApplicationApplication for quotation of securities - BDXNotification of cessation of securities - BDXNotification of cessation of securities - BDXChange of Director's Interest NoticeQuarterly Activities/Appendix 4C Cash Flow ReportComments
2026-11-17 · Health care
BDX: $0.060 +0.00% · MC: $22M
BCAL Diagnostics has received ethics approval to expand its breast cancer research to multiomic assay development, including investigation of epigenomic biomarkers. Its lipidomics research framework has been published in a peer-reviewed journal, while a second paper remains under revision after peer review; an abstract on a blood-based assay for breast cancer recurrence has been accepted for a December symposium.
Updated 2026-11-17 08:49
Sources
BCAL Expands Breast Cancer Biomarker ProgramComments
2026-11-13 · Health care
BDX: $0.060 -1.64% · MC: $22M
BCAL Diagnostics, which holds 18.46% of Genetic Signatures, has asked the Takeovers Panel to intervene in Genetic Signatures’ proposed merger with Microba, arguing the deal terms could restrict competing offers and shareholders lack sufficient time and information; the Panel has not decided whether to conduct proceedings. Separately, BCAL issued ordinary shares to employees under its incentive scheme, while performance rights lapsed and options expired.
Updated 2026-11-13 17:52
Sources
TOV: GSS - Panel Receives ApplicationApplication for quotation of securities - BDXNotification of cessation of securities - BDXNotification of cessation of securities - BDXComments
2026-11-11 · Health care
BDX: $0.064 +0.00% · MC: $22M
BCAL Diagnostics director Jayne Shaw acquired 72,315 shares on market, increasing the holding in her family account while her other disclosed holdings remained unchanged. The purchase was made on 5 November.
Updated 2026-11-11 15:49
Sources
Change of Director's Interest NoticeComments
2026-10-30 · Health care
BDX: $0.084 +5.00% · MC: $22M
BCAL Diagnostics completed clinical validation of BREASTESTplus 2 for women aged 30 and over across all breast densities, with a launch targeted for November subject to accreditation and operational readiness. Avantect Multicancer is now available at select Sydney and Melbourne locations, while preparations continue for a broader rollout. BCAL also increased its strategic interest in Genetic Signatures to approximately 18%, acquiring additional shares for $2 million.
Updated 2026-10-30 11:43
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
Comments